354 related articles for article (PubMed ID: 37288355)
1. Rethinking the potential and necessity of drug delivery systems in neovascular age-related macular degeneration therapy.
Huang X; Zhang L; Fu Y; Zhang M; Yang Q; Peng J
Front Bioeng Biotechnol; 2023; 11():1199922. PubMed ID: 37288355
[TBL] [Abstract][Full Text] [Related]
2. Novel Treatments for Age-Related Macular Degeneration: A Review of Clinical Advances in Sustained Drug Delivery Systems.
Jiménez-Gómez Y; Alba-Molina D; Blanco-Blanco M; Pérez-Fajardo L; Reyes-Ortega F; Ortega-Llamas L; Villalba-González M; Fernández-Choquet de Isla I; Pugliese F; Stoikow I; González-Andrades M
Pharmaceutics; 2022 Jul; 14(7):. PubMed ID: 35890368
[TBL] [Abstract][Full Text] [Related]
3. Novel Approaches in the Drug Development and Delivery Systems for Age-Related Macular Degeneration.
Paliwal H; Prajapati BG; Srichana T; Singh S; Patel RJ
Life (Basel); 2023 Feb; 13(2):. PubMed ID: 36836923
[TBL] [Abstract][Full Text] [Related]
4. Development of gene therapy for treatment of age-related macular degeneration.
Askou AL
Acta Ophthalmol; 2014 Jul; 92 Thesis3():1-38. PubMed ID: 24953666
[TBL] [Abstract][Full Text] [Related]
5. Combined treatment modalities for age related macular degeneration.
Das RA; Romano A; Chiosi F; Menzione M; Rinaldi M
Curr Drug Targets; 2011 Feb; 12(2):182-9. PubMed ID: 20887244
[TBL] [Abstract][Full Text] [Related]
6. [Novel approach for management of age-related macular degeneration--antiangiogenic therapy and retinal regenerative therapy].
Tamaki Y
Nippon Ganka Gakkai Zasshi; 2007 Mar; 111(3):232-68; discussion 269. PubMed ID: 17402564
[TBL] [Abstract][Full Text] [Related]
7. Current therapeutic approaches in neovascular age-related macular degeneration.
Nguyen DH; Luo J; Zhang K; Zhang M
Discov Med; 2013 Jun; 15(85):343-8. PubMed ID: 23819948
[TBL] [Abstract][Full Text] [Related]
8. Profile of conbercept in the treatment of neovascular age-related macular degeneration.
Lu X; Sun X
Drug Des Devel Ther; 2015; 9():2311-20. PubMed ID: 25960634
[TBL] [Abstract][Full Text] [Related]
9. Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration.
Becerra EM; Morescalchi F; Gandolfo F; Danzi P; Nascimbeni G; Arcidiacono B; Semeraro F
Curr Drug Targets; 2011 Feb; 12(2):149-72. PubMed ID: 20887246
[TBL] [Abstract][Full Text] [Related]
10. Nanotechnology for Age-Related Macular Degeneration.
Yang B; Li G; Liu J; Li X; Zhang S; Sun F; Liu W
Pharmaceutics; 2021 Nov; 13(12):. PubMed ID: 34959316
[TBL] [Abstract][Full Text] [Related]
11. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration.
Moja L; Lucenteforte E; Kwag KH; Bertele V; Campomori A; Chakravarthy U; D'Amico R; Dickersin K; Kodjikian L; Lindsley K; Loke Y; Maguire M; Martin DF; Mugelli A; Mühlbauer B; Püntmann I; Reeves B; Rogers C; Schmucker C; Subramanian ML; Virgili G
Cochrane Database Syst Rev; 2014 Sep; 9(9):CD011230. PubMed ID: 25220133
[TBL] [Abstract][Full Text] [Related]
12. [Guidance for the treatment of neovascular age-related macular degeneration (AMD)].
Karska-Basta I; Kubicka-Trzaska A; Oleksy P; Romanowska-Dixon B
Przegl Lek; 2009; 66(11):972-5. PubMed ID: 20297641
[TBL] [Abstract][Full Text] [Related]
13. Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema.
Fong AH; Lai TY
Clin Interv Aging; 2013; 8():467-83. PubMed ID: 23766636
[TBL] [Abstract][Full Text] [Related]
14. Clinical protocol. An open-label, phase I, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD).
Rasmussen H; Chu KW; Campochiaro P; Gehlbach PL; Haller JA; Handa JT; Nguyen QD; Sung JU
Hum Gene Ther; 2001 Nov; 12(16):2029-32. PubMed ID: 11727737
[TBL] [Abstract][Full Text] [Related]
15. Anti-VEGF agents for age-related macular degeneration.
Ozkiris A
Expert Opin Ther Pat; 2010 Jan; 20(1):103-18. PubMed ID: 20021287
[TBL] [Abstract][Full Text] [Related]
16. Disease progression pathways of wet AMD: opportunities for new target discovery.
Wolf AT; Harris A; Oddone F; Siesky B; Verticchio Vercellin A; Ciulla TA
Expert Opin Ther Targets; 2022 Jan; 26(1):5-12. PubMed ID: 35060431
[TBL] [Abstract][Full Text] [Related]
17. Emerging biological therapies for the treatment of age-related macular degeneration.
Asahi MG; Avaylon J; Wallsh J; Gallemore RP
Expert Opin Emerg Drugs; 2021 Jun; 26(2):193-207. PubMed ID: 34030572
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Port Delivery System with ranibizumab for the treatment of neovascular age-related macular degeneration.
Patel AJ; Pieramici DJ; Bagheri N
Ther Deliv; 2021 Mar; 12(3):191-200. PubMed ID: 33641347
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Potential of the Ranibizumab Port Delivery System in the Treatment of AMD: Evidence to Date.
Chen ER; Kaiser PK
Clin Ophthalmol; 2020; 14():1349-1355. PubMed ID: 32546942
[TBL] [Abstract][Full Text] [Related]
20. Neovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming Approaches.
Ricci F; Bandello F; Navarra P; Staurenghi G; Stumpp M; Zarbin M
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33153227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
